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Summary. Cancer is the subject of intense research
around the world, but many questions about how the
disease works remain unanswered. How exactly does
cancer start and how do tumours grow? In fact, at
present there are ten times more anticancer drugs being
tested in clinical trials than there were 15 years ago.
However, many of the new anticancer agents are
predicted to show clinical benefit in only small
subpopulations of patients. The cancer stem cell model
could explain not only how some cancers work but also
why patients suffer relapses, providing a good
opportunity to gain insight into the reasons why agents
work or, more commonly, don’t work, before going into
a clinical trial.
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Cancer and treatments
It is now widely accepted that cancer results from
the accumulation of mutations in the genes that directly
control cell birth or cell death (Hanahan and Weinberg,
2000). But the mechanisms through which these
mutations are generated are the subject of continuing
debate. In addition, the microenvironment of a tumour,
including stromal and vascular endothelial cells, is
important for the growth and persistence of the tumour
(Hanahan and Weinberg, 2000). This entire constellation
of the abnormal molecular biology of tumour cells and
their microenvironment is the molecular signature of
cancer.
It has been argued that an underlying genetic
instability is absolutely required for the generation of the
multiple mutations that underlie cancer (Loeb, 1991;
Hartwell, 1992). It is only in recent years that the
involvement of specific genes has been demonstrated at
the molecular level in most cancers. Cancer cells arise
from normal cells through the acquisition of a series of
mutations in oncogenes and tumour suppressor genes
(Hanahan and Weinberg, 2000). The current working
hypothesis on the origin of cancer proposes that the
accumulation of somatic mutations in certain functional
pathways leads to deregulated proliferation (Jackson and
Loeb, 1998; Lengauer et al., 1998). Genetic pathways
need to be identified for the development of molecular
and pharmacological therapeutics to treat and prevent
cancer. However, cancer is a disease of the organism and
not only the result of abnormal cell growth. This may
explain why genetic diseases like cancer are
underprovided in ethiologic treatments (Sanchez-Garcia
et al., 2007), explaining that the relative survival
considering the stage of diagnosis has not changed for
the past three decades (Etzioni et al., 2003). Current
observed decrease in cancer mortality is mostly the
result of early detection and prevention rather than the
consequence of effective therapeutics.
Much effort is currently being expended to target,
during treatment, the mutated oncogenes and tumour
suppressor genes that control neoplastic cell growth
directly. The genetic instabilities that underlie cancer
may provide equally valid therapeutic targets. Although
such instabilities are not directly responsible for cancer’s
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abnormal growth, they are likely to be genetically based
and, therefore, permanent components of the cancer cell
that distinguish it from all normal cells. Because
instabilities reflect defects in cellular processes that
maintain the integrity of the genome, they can be
expected to generate sensitivities to particular chemical
agents (Lengauer et al., 1998). In fact, one can argue
persuasively that all chemotherapeutic compounds used
at present are more toxic to cancer cells than to normal
cells only, specifically because of the defective
checkpoints that occur in the former cells (Hartwell,
1992). 
Conventional chemotherapy
The era of chemotherapy began in the 1940s with
the first uses of nitrogen mustards and antifolate drugs.
Cancer drug development since then has been
transformed from a low-budget, government-supported
research effort to a high-stakes, multi-billion dollar
industry (Chabner and Roberts, 2005). 
Cytotoxic chemotherapy or radiotherapy of cancer is
limited by serious, sometimes life threatening, side
effects that arise from toxicities to sensitive normal cells
because the therapies are not selective for malignant
cells (Allen, 2002). Cancer cells share many common
features with the normal host cells from which they
derive. Most, if not all, cancer chemotherapeutics that
are in common use at present- including doxorubicin,
vincristine, cyclophosphamide, topotecan and paclitaxel-
owe what little selectivity they have for cancer cells to
their higher proliferation rates. This can lead to
increased toxicities against normal tissues that also show
enhanced proliferative rates, such as bone marrow,
gastrointestinal tract and hair follicles. All these caveats
result in the eventual failure of therapy; this is often
accompanied by the development of drug resistance and
metastatic disease (Allen, 2002). 
Several approaches for improving the selective
toxicity of anticancer therapeutics are being pursued at
present.
Targeted therapy
While the attempts to improve the pace of discovery
of cytotoxic agents proceeded in the late 1980s,
molecular and genetic approaches to understand cell
biology uncovered entirely new signaling networks that
regulate cellular activities such as proliferation and
survival (Jackson and Loeb, 1998; Lengauer et al.,
1998). Many of these networks were found to be
radically altered in cancer cells. An industrial revolution
unfolded, based primarily on small biotechnology firms,
as researchers set out to repair these molecular defects in
cancer cells, beginning the era of “targeted therapy”
(Chabner and Roberts, 2005). 
The term “targeted therapy” refers to a new
generation of cancer drugs designed to interfere with a
specific molecular target (typically a protein) that is
believed to have a critical role in tumour growth or
progression. The identification of appropriate targets is
based on a detailed understanding of the molecular
changes underlying cancer. This approach contrasts with
the conventional, more empirical approach used to
develop cytotoxic chemotherapeutics- the mainstay of
cancer drug development in past decades (Allen, 2002;
Sawyers, 2004). The hope is that such therapeutics will
selectively target tumour cells and leave normal cells
untouched, thereby reducing the common side effects of
current anticancer therapies such as radio- and
chemotherapy (Sullivan and Kelloff, 2005). There is an
increasing number of such targeted therapeutics being
developed and made available for clinical use (Table
1).The new targets included growth factors, signaling
molecules, cell-cycle proteins, modulators of apoptosis
and molecules that promoted angiogenesis (Hanahan and
Weinberg, 2000).
One of the landmark events in the targeted
revolution has been the development of Imatinib
mesylate (Gleevec), a relatively simple structure that
possesses all the desired factors of the “ideal” targeted
compound (Mauro and Druker, 2001a). It was derived
from a natural product by Novartis. Imatinib is a
moderately potent inhibitor of the kinase BCR-ABL, the
fusion protein product of a chromosomal translocation,
named Philadelphia chromosome (Ph), which is
involved in the pathogenesis of chronic myeloid
leukaemia (CML) (Chabner and Roberts, 2005; Mauro
and Druker, 2001b; Druker et al., 2001). Brian Druker
and collaborators showed that when Imatinib is used to
treat patients with chronic-phase CML, 90% seem to
achieve complete haematological remission and many
lose cytogenetic evidence of the malignant clone
(Druker et al., 2001).  However, BCR-ABL translocation
can still be detected by PCR analysis in cells of most
patients (Mauro and Druker, 2001a; Druker et al., 2001).
In the acute leukaemic phase of CML, Imatinib induces
brief remissions, and treatment leads to a rapid
outgrowth of drug-resistant cells that display mutations
in the catalytic kinase domain of ABL (Shah et al.,
2002). The origin of CML begins in a hematopoietic
stem cell (HSC), a target population that is largely
quiescent (Spangrude et al., 1988).  In vitro and in vivo
studies in the last years have shown that these quiescent
Ph+ HSCs, the origin of CML, are insensitive to
Imatinib mesylate treatment (Graham et al., 2002; Chu et
al., 2005), and are not eliminated in CML patients.
Imatinib mesylate inhibits malignant primitive
progenitor growth primarily through inhibition of their
abnormally increased proliferation rather than selective
induction of apoptosis (Bhatia et al., 2003). This
suggests that BCR/ABL kinase activity may be required
for abnormal proliferation and expansion of Ph+ cells in
CML but may not be essential for preservation of
primitive malignant cells. BCR-ABL kinase inhibition
by Imatinib mesylate may therefore remove the
proliferative advantage of Ph+ progenitors and their
progeny cells allowing regrowth of coexisting Ph- cells
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without eliminating all Ph+ primitive progenitors. In
conclusion, although Imatinib mesylate therapy is able to
suppress the oncogenic activity of wild-type BCR-ABL
expression, the treatment is unable to destroy the Ph+
cancer stem target cell (Perez-Caro et al., 2009; Vicente-
Dueñas et al., 2009).
The transition from cytotoxic drugs to targeted
therapies represents an important advance, but the basic
principles of cancer treatment and drug resistance, as
developed in the period from 1950 to 1980, remain the
same (Chabner and Roberts, 2005). Human malignancies
seem to be a very diverse group of diseases, even within
histological classifications, and quickly display their
diversity when exposed to all forms of chemotherapy.
The next decade will present the challenge of designing
trials to combine targeted drugs and cytotoxics in a more
effective manner. These trials will be aided by the use of
genomics and molecular assays to identify subsets of
patients that are most likely to respond to certain drugs,
thereby avoiding the needless cost and toxicity of
ineffective treatment (Chabner and Roberts, 2005). 
All these targets work on targeting of proliferation
controls in agreement with the current working
hypothesis on the origin of cancer, which proposes that
the accumulation of somatic mutations in certain
functional pathways leads to deregulated proliferation
(Jackson and Loeb, 1998; Lengauer et al., 1998).
However, despite the promise of rational treatment,
many researchers have serious doubts as to whether this
is a viable approach (Sanchez-García et al., 2007;
Sánchez-García, 2009). Many of the new classes of
agents are predicted to show clinical benefit in only
small subpopulations of patients, if at all, and target non-
essential aspects of tumour maintenance and
development. How can cancer treatment development be
re-designed to select effective targeted anticancer drugs?
Limitation in our knowledge of human cancer:cancer
stem cells
Human cancer as a stem cell disease
It is well-known that cancer is a clonal disease that
initiates in a single cell whose descendants make up the
tumour. However, the cell nature in which the initiating
mutation takes place in human cancer has received little
attention during the last decades (Cobaleda and Sánchez-
García, 2009). An enduring idea in cancer biology is that
tumours arise and grow as a result of the formation of
cancer stem cells, which may constitute only a minority
of the cells within a tumour but are nevertheless critical
for its propagation. The concept of cancer stem cells
dates back almost as far as the discovery of somatic stem
cells in the haematopoietic system, and was firmly
established experimentally in acute leukemias (Bonnet
and Dick, 1997; Cobaleda et al., 2000; Shet et al., 2002;
Sanchez et al., 1995; Sanchez-Garcia et al., 1999).
Indeed, the key role of stem cells in human
tumorigenesis is becoming an increasingly accepted
phenomenon and has been the issue of recent reviews
(Reya et al., 2001; Ruiz i Altaba et al., 2002). As stem
cells and cancer cells share a great number of features, it
would certainly make sense that human cancers derive
from stem cells, especially as stem cells, like cancer
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Table 1. Main new targeted drugs to treat cancer.
Cancer/Drug Action Clinical Benefit* Preclinical trials in mouse Reference
model reproducing human cancer
Colorectal cancer
Bevacizumab (Avastin®) Angiogenesis inhibitor ? NO Venook, 2005
Cetuximab (Erbitux®) EGFR inhibitor ? NO Venook, 2005
Irinotecan (Campo®) Topoisomerasa I inhibitor ? NO Venook, 2005
Capecitabine (Xeloda®) Inhibits DNA/RNA synthesis ? NO Venook, 2005
Oxaliplatin (Eloxatin®) Inhibits DNA/RNA synthesis ? NO Venook, 2005
Multiple myeloma
Bortezomib (Velcade®) Proteasome inhibitor ? NO Chang et al., 2005
Lung cancer
Gefitinib (Iressa®) EGFR tyrosine kinase inhibitor ? NO Pal and Pegram, 2005
Erlotinib (Tarceva®) EGFR tyrosine kinase inhibitor ? NO Pal and Pegram, 2005
Chronic myeloid leukemia
Imatinib mesylate (Gleevec®, Glivec®) Tyrosine kinase inhibitor ? NO Graham et al., 2002; Chu et al., 2005
Breast cancer
Exemestane (Aromasin®) Aromatase inhibitor ? NO Joensuu et al., 2005
Letrozole (Femara®) Aromatase inhibitor ? NO Joensuu et al., 2005
Anastrozole (Arimidex®) Aromatase inhibitor ? NO Joensuu et al., 2005
Tamoxifen Oestrogen receptor antagonist ? NO Delozier, 2005
Fulvestrant (Faslodex®) Oestrogen receptor antagonist ? NO Bundred, 2005
The absence of adapted preclinical trials in mouse models reproducing human cancer is the bottleneck preventing compounds from showing a clinical
benefit on clinical trials. *: The symbol (?) means that sustainable long-term survival benefit has not been formally demonstrated yet.
cells, are immortal, poorly differentiated cell types that
regularly express certain key survival genes (Greaves,
1996). Supporting this view, recent results suggest that a
stem cell constitutes the target cell in human breast
carcinomas and brain tumours (Al-Hajj et al., 2003).
These results indicate that we must view cancer as a
disease of cell differentiation rather than multiplication.
Implication of the stem cell model for development of
cancer treatments
Cancers consist of heterogeneous populations of
cancer cells that differ markedly in their ability to
proliferate and form new tumours. While the majority of
cancer cells have a limited ability to divide, a population
of cancer stem cells that has the exclusive ability to
extensively proliferate and form new tumours can be
identified based on marker expression. Growing
evidence suggests that pathways that regulate the self-
renewal of normal stem cells are deregulated in cancer
stem cells, resulting in the continuous expansion of self-
renewing cancer cells and tumour formation (Al-Hajj et
al., 2004; Clarke, 2005). This suggests that agents that
target the defective self-renewal pathways in cancer cells
might lead to improved outcomes in the treatment of
these diseases (Al-Hajj and Clarke, 2004). 
This observation has implications for the biology of
tumour formation as well as the diagnosis and treatment
of cancer. To treat cancer effectively, the CSCs must be
eliminated (Sanchez-Garcia et al., 2007; Perez-Caro et
al., 2009; Vicente-Dueñas et al., 2009). Otherwise, the
tumour will rapidly reform if the therapy eliminates non-
tumourigenic cancer cells but spares a significant
population of CSCs (Al-Hajj and Clarke, 2004).
Classically, treatments for cancer have relied on the
ability to shrink tumours. Since in many cases the CSCs
represent a minority cell population of the tumour (Al-
Hajj et al., 2003; Lapidot et al., 1994; Singh et al., 2003,
Matsui et al., 2004; Setoguchi et al., 2004), agents
selectively killing the CSCs are likely overlooked in our
current screening methods, which rely on rapid reduction
of tumour size. If an agent spares a significant number of
the CSCs, then the remaining cells could rapidly reform
the tumour (Clarke, 2005) (Fig. 1). In addition to its
effect on our understanding of the efficacy of our current
therapies, the stem cell model for cancer is likely to
affect the identification of future therapeutic targets. By
directing expression analyses to an enriched population
of tumorogenic cancer cells, the identification of novel
diagnostic markers and novel therapeutic targets should
be more effective. In addition, it is becoming apparent
that treatments that directly target the pathways involved
in maintenance of CSC would have a significantly
greater chance of success (Castellanos et al., 2010;
Sanchez-Garcia, 2010).
The efficacy of anti-tumor agents in clinical trials is
commonly evaluated following RECIST (Response
Evaluation Criteria In Solid Tumors) rules that define
when cancer patients improve ("respond"), stay the same
("stable") or worsen ("progression") during treatments,
which are based on tumor size.  Since it is the bulk of
tumor cells, non CSCs, which make up most of the
tumor mass, efficacy mainly reflects the ability to kill
those non CSCs.  The identification of CSC biomarkers
will certainly allow direct evaluation of the effect of
anti-tumor agents on these minor populations.  Therefore
not tumor size reduction but instead complete response
(CR) is a valid end point when associated with reduced
recurrence rate.  An agent that only targets CSCs is
predicted to show only a moderate effect on tumor size
but would have a dramatic effect preventing tumor
recurrence; on the other hand, an agent that targets the
bulk of tumor cells but not CSC self-renewal will
initially show good clinical response but will not prevent
recurrence.  This trial may result in a failure because of
evidence of tumor progression.  It is necessary to
introduce recurrence in the adjuvant setting to identify
effective CSC targeting agents.  
If we assume that the genetic alteration responsible
for cancer development takes place in the CSC, we can
design mouse models based on this issue (Vicente-
Dueñas et al., 2010). However we must focus on
determining what the process responsible for the
maintenance of the CSC phenotype is, because this will
be the aim for the new identification of targets to design
drugs against them. So, mouse models generated this
way, will become the basic tool to design drugs in this
context, against the maintenance of the CSC.
How to apply the new agents in appropriate clinical
settings
Pharmaceutical companies are conducting more
clinical trials than ever before and more patients are
participating in these trials, though the number of drugs
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Fig. 1.Targeting cancer stem cells. Cancer is considered a proliferative
disease (Jackson and Loeb, 1998; Lengauer et al., 1998) and current
therapies are designed against these mechanisms. These therapies
have not obtained a therapeutic benefit in the majority of cases (Graham
et al., 2002; Chu et al., 2005).The tumour initially shrinks, but the self-
renewing cancer stem cell regenerates the tumour. Recent results
support cancer as a stem cell disease, so drugs that target the
mechanism responsible for the maintenance of CSCs will eliminate the
CSCs and thus have curative potential.
that have a real benefit has not increased. A very
important cause of the inefficiency of the discovery and
development process is the disparity between preclinical
and clinical trials. Most often, anticancer effects seen in
the preclinical state (on cells or animal models) cannot
be replicated in humans. Almost unanimously
recognized factors leading to this disparity are: lack of
predictive animal models, absence of diagnostic and
monitoring biomarkers and scarcity of properly oriented
therapeutic strategies.
Thus, a clinical trial has become an assay to validate
targets in a particular disease state, so that we need
models mimicking human cancer in which to validate
those targets. Current preclinical settings do not
accurately predict clinical efficacy of that target in
humans (Perez-Caro et al., 2009; Vicente-Dueñas et al.,
2009). On the other hand, moving all targets forward
through development is prohibitive in terms of cost and
time and therefore rational choices between novel targets
have to be made. The need for a good in vivo model can
present a strong case for validation. However,
modulation of many targets put forward for small
molecules or biopharmaceutical development fails to
reverse the disease phenotype in humans. Therefore, a
greater need to bridge the gap between disease models
and the clinic exists. Validation of targets in a disease
state mimicking human disease will provide us the
platform for high-value target validation. 
There are many steps in developing a new putative
agent and then using it as a drug (Table 2). First of all,
we must select the targets needed for the maintenance of
the CSC. These targets will be different from those that
had transformed normal stem cell to CSC. If we can
reverse the effect of the aberrant maintenance of CSC,
we could probably treat the disease. To select these
unknown targets, we can take advantage of mouse
models based on CSC alterations that accurately
reproduce the human disease from stem cells. The next
step is validating these new targets in a disease state by
mouse genetics tools plus molecular imaging and
pharmacogenomics approaches. Targets validated this
way should be tested on mouse models mimicking
human disease pathology. After that, we must single out
those animals that are sensible to the agents from the
ones that are not. These results should guide us on
deciding whether or not to use that agent on human
clinical trials, so we are improving current preclinical
trials because we can be more selective and effective.
Taking these results to mouse models, we could define
which models will respond to the agents through genetic
profile analysis, so that we can use these data in human
clinical trials. Keeping in mind preclinical assay results
we must design human clinical trials (Table 2). So
instead of selecting patients in a random manner, we
should study the genetic profile of each patient and make
homogeneous groups sharing similar genetic profiles. In
this regard Pharmaco-genomics has a lot to say as we
discuss later. The clinical setting proposed herein will
reduce the number of agents that goes into clinical trials,
being able to expend more effort on ones with a potential
benefit. 
Mouse models of human cancer
The generation of mouse models that accurately
mimic human cancer must take into account two main
criteria: i) the genetic/molecular alterations identified in
human cancer and also ii) the target cells where the
cancer-mutation takes place in humans. These target
cells may be somatic stem/primitive cells, identifying
them as the cells to be used as targets in the development
of both mouse models and molecular and pharmaceutical
therapeutics to treat and prevent human cancers (Pérez-
Caro et al., 2005). This second criterion has not been
taken into account in the design of current models of
human cancer and may explain why many mouse models
of cancer might be inadequate (Pérez-Caro et al., 2009;
Vicente-Dueñas et al., 2009, 2010). 
Numerous agents have shown exciting activity in
preclinical models and yet have had minimal activity
clinically. These disappointments have led to reasonable
skepticism about the true value of both syngeneic and
xenograft rodent tumour models in accurately
identifying agents that will have important clinical utility
(Peterson and Houghton, 2004). Whereas the
development of newer techniques, including transgenic
mouse models of cancer, offers the potential to develop
more predictive models, the role of such mice in cancer
drug development is not yet validated.
Biological criteria to confirm the same genotype-
phenotype correlations in human and mice need to be
used to validate the model, such as:
i) Similar histological features to the homologous
human tumour.
ii) Progression through the same stages and equal
systemic effects in the host.
iii) Same genetic pathways should be affected in
tumour initiation and progression.
iv) Response to current cancer treatments should be
similar to humans.
Current mouse models
Technical advances over the past two decades now
allow investigators to introduce alterations in the mouse
genome that constitutively or conditionally alter the
expression of crucial genes, leading to the development
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Table 2. Steps on developing new agent in appropiate clinical settings.
a) To select targets for CSC maintenance.
b) To validate target in adisease state (by mouse genetic tools*).
c) To select responders vs. ne responders.
d) Design human clinical trials.
*: Molecular Image (same technology approach need to follow up
human cancer); *: Pharmacogenomics.
of particular tumours. These studies have provided
tremendous insights into all aspects of cancer research
and have further defined the biological functions of
hundreds of genes. Genetically engineered mouse
models (GEM) have helped to elucidate the molecular
pathways involved in oncogenesis, to define the effects
of particular mutations or gene deletions on cancer
development, and have been useful for validating key
genes as targets for therapy. More recently, these models
have been used to test targeted therapies, cancer
vaccines, preventive agents and combinations of
chemopreventive and/or therapeutic agents (Green and
Hudson, 2005). The selective use of GEM models has
proved valuable for assessing the in vivo inhibitory
activities and mechanisms of action of various cancer
prevention agents at different stages of cancer
development.
The evaluation of antitumour agents in immune-
deficient mice transplanted with human tumours is the
major model system for drug development. In its most
simple iteration, tumours are grown subcutaneously, and
the model allows rapid and quantifiable assessment of
antitumour activity relative to mouse toxicity (Johnson
et al., 2001). Logically, preference should be given to
those agents that show the greatest antitumour activity in
the preclinical setting, but these preclinical data are not
predictive of drug activity in human studies. Xenograft
models do not take into account CSC. 
GEM models, which develop tumours over a
relatively short time compared with the emergence over
many years of many human cancers, offer several
potential advantages over tumour xenograft or
chemically-induced rodent cancer models. Unlike
xenograft or chemically-induced models, chemo-
preventive responses can be assessed for tumours that
arise as a result of specific, engineered genetic lesions
introduced into the mouse genome. Moreover, genetic
and environmental factors can be controlled rigorously
in mice, but remain poorly controlled variables in human
trials. Whereas xenograft models generally represent an
advanced stage of cancer and are not suitable for studies
of early stages of tumorigenesis, cancer stage-specific
responses to agents can be assessed in many GEM
models in which lesions progress through predictable
stages. Combinations of therapies and/or preventive
agents, which are difficult to test in human trials, can
readily be evaluated using GEM models to determine the
biological consequences of interfering simultaneously
with multiple oncogenic pathways. 
The generation of mouse models of human cancer
has become increasingly sophisticated and relevant for
the pre-clinical testing of prevention agents (Vicente-
Dueñas et al., 2010). Much recent attention has been
devoted to determining how well the cancers of GEM
models resemble human cancers. Initially, such
comparisons were based on the biological properties and
morphological characteristics of the mouse tumours
(Cardiff et al., 2000; Boivin et al., 2003), but more
recently, comparative genomic hybridization (Weaver et
al., 2002) and gene-expression profiling have allowed
molecular dissection and comparisons of genes that are
aberrantly expressed in both human and mouse cancers
(Desai et al., 2002; Hunter et al., 2003). This analysis
allows researchers to compare how well different models
replicate molecular aspects of oncogenesis, thereby
helping to identify models that are particularly relevant
for prevention studies.
The molecular dissection of human cancers
continues to identify important genes, pathways and
networks that are crucial to tumour progression. This
information is being integrated into the new generation
of GEM models. The use of strong promoters to drive
the expression of oncogenes might bypass crucial
mechanisms that are important in naturally occurring
tumorigenesis, such as genomic instability and
additional genetic and epigenetic changes. Promising
new models have recently been developed and can be
used for the preclinical testing of preventive agents
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Fig. 2. Why do current mouse models not
reproduce human cancer? Many available
current mouse models only take into account
the genetic alteration found in human cancers
without considering the cellular context where it
takes place. New mouse models that accurately
reproduce human cancer express the genetic
alteration responsible for cell transformation in
the target cell where the cancer-mutation takes
place in humans, the cancer stem cell (CSC).
CSCs can be derived from normal stem cells
that have acquired a genetic alteration. On the
other hand, CSCs could arise from non stem
cells that have gained the ability to self-renew
and then became a stem cell.
(Perez-Caro et al., 2009; Vicente-Dueñas et al., 2009;
Blasco et al., 2011). 
The main reason why current mouse models have
failed in being predictive for clinical trials is that all of
them have only taken into account the genetic/molecular
alteration identified in human cancer (Fig. 2). The target
cells in which the cancer-mutation takes place in humans
have not been taken into account. This may explain why
many mouse models of cancer might be inadequate. In
these models the mutation occurs in every cell of the
organism or tissue, unlike the genetic lesions in human
cancer that occur sporadically in single cells during
prental or postnatal development.
How to model human cancer in mice?
To be able to model human cancer in mice we
should identify the genetic alteration responsible for cell
transformation and also identify the cell in which the
alteration takes place. These models mimicking human
cancer must be validated by comparative genomics and
pathology. Live animal imaging will also enable the
estimation of functional genomics and target validation. 
We propose a new mouse model technology based
on specifically expressing human genetic alterations in
somatic stem cells, by means of stem cell-restrictive
promoters. The application of this technology has
generated the first mouse models of human cancer that
accurately reproduce the human disease (Fig. 2) (Perez-
Caro et al., 2009; Vicente-Dueñas et al., 2009).
“Humanized” mouse models of mesenchymal cancer
have been produced, in which the disease originates and
evolves spontaneously in the correct environment, only
in a few cells that accumulate further cancerous
mutations once the initial, triggering oncogene is
activated. Carcinoma models are also being developed
using the same strategy. For these reasons, they are
unique experimental tools for in vivo functional
genomics, pharmacogenomics and drug discovery
programs. They are also an invaluable source of
biological materials (cells, tissues, fluids) with which to
conduct in vitro genetic studies and pharmacological
screenings. 
Collection of tissues from models mimicking human
cancer at time points that correspond with maximal
clinical effect will provide the best opportunity to gain
insight into the reasons agents work or, more commonly,
don’t work, before going into a clinical trial.
The problem of cancer heterogeneity
Cancer is an heterogeneous disease; indeed, patients
that share the same apparent histopathological tumor
lesion, present the same stage of the disease, and even
receive the same therapy, could show a completely
different evolution. Moreover, individuals under the
same environment, and similar doses of carcinogens
along their lives might or might not develop cancer, and
the time of latency is variable, as occurs with heavy
smokers or with people exposed to nuclear radiation
(Carmichael et al., 2003; Aguirre-Ghiso, 2007; Slamon
et al., 2001; Smigal et al., 2006; Winter and Hunter,
2008). This heterogeneity of cancer susceptibility,
evolution and response to therapy is explained by the
sum of effects of different low-penetrance genes (named
modifier genes) that interact among them and with the
environment (Balmain, 2002). Thus, cancer can be
considered as a polygenic disease whose heterogeneous
evolution would follow a model of quantitative genetics.
The identification of those modifier polygenes is a
difficult task mainly due to their weak individual effect.
Genome Wide Association Studies (GWAS) in human
populations have already identified good candidates, but
the extrapolation of these results to different populations
seems to be difficult due to heterogeneous human
genetics and complex environmental interactions
(Balmain, 2002; Hunter and Crawford, 2008).
Mice develop tumors that appear to be very similar
to human cancer, and involve mutations with a similar
spectrum, affecting the same genes and pathways as in
human cancer (Balmain and Harris, 2000). So we can
anticipate that part of the numerous Quantitative Trait
Loci (QTL) containing tumor risk genes identified in the
mouse could be relevant to the human scenario, and
would serve to complement observations taken within
human populations (Balmain, 2002).  New cancer mouse
models, together with the crosses between inbred mouse
strains with homogeneous genetic background that show
different grades of cancer susceptibility and evolution,
can really simplify the identification of cancer modifier
genes, because they permit a higher control of hereditary
variation and environmental exposure (Hunter and
Crawford, 2008). These mouse genetic studies permit
the identification of QTL in which modifier genes are
located. These QTL can include both types of modifier
genes, those regulating intrinsic cellular characteristics
(proliferation, apoptosis, DNA repair and others), other
controlling extracellular factors (stroma, angiogenesis,
immune system, endocrine factors, etcetera), and those
that participate simultaneously in both functions.
Mouse models also offer a system for testing results
obtained from human studies. Thus, moving back and
forth between mouse and human systems is a good
approach to identify the causal genetic variant of a
candidate gene. Moreover, since environmental
influences and way of life have a significant effect on
tumour susceptibility, environment-genome interactions
could be explored by the use of mouse models, and will
eventually allow us to recognize how genes work
together with environmental influences identified by
epidemiological studies (Quigley and Balmain, 2009).
Identification of modifier genes in mouse models
Although the mouse is an effective tool to map QTL
this strategy is not without problems (Hunter and
Crawford, 2008). In particular, the deficiency of
mapping resolution makes it difficult to identify those
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modifier genes associated with complex genetic traits,
such as cancer. New technological approaches have
permitted us to relieve this caveat. The analysis of
tumors using whole genome array comparative genomic
hybridization (aCGH) and loss of heterozigosity (LOH)
analysis by SNParrays, is helping to refine QTL regions.
It is known that, similar to what happens with high
penetrance susceptibility genes, tumors are marked by
mutations on those genes implicated in susceptibility.
The same would occur with at least part of the low-
penetrance susceptibility genes that control intrinsic
cellular activities. Low-susceptibility tumor genes would
drive copy number changes in tumors in an allele-
specific manner, therefore cancer resistance alleles
would be lost along tumor progression as a result of
deletion or recombination leading to loss of
heterozigosity (LOH), whereas cancer risk genes would
show gains through amplification. These types of allele
specific somatic losses and gains can be exploited to
identify modifier genes of cancer susceptibility and
evolution (Ewart-Toland et al., 2005; Balmain et al.,
2003). This strategy facilitated the recognition of Stk6 as
a low-penetrance tumor susceptibility gene (Ewart-
Toland et al., 2003).
The use of genome-wide expression arrays is also a
useful technique to refine QTL. The observation that the
majority of SNPs are located out of coding regions
suggest the hypothesis that many QTLs were probably
attributed to alterations in gene expression instead of to
mutations within coding regions, as is the case of Kras2
in cancer induced by urethane (To et al., 2006). This idea
has consequently resulted in the screening for genes in
QTL that exhibit differential expression among the
strains of interest (Arbilly et al., 2006).  This strategy
permits a fast screening of hundreds of possible
candidate modifier genes (Hitzemann et al., 2002;
Jansen and Nap, 2001; DiPetrillo et al., 2005). Genome
wide expression arrays also permit the generation of co-
regulated networks of transcripts from genes that are
working collectively to modify a particular tumor
phenotype of susceptibility and evolution.  Each network
would be constituted by those transcripts that
significantly correlated with each other, and whose
expression levels are controlled by common genetic loci.
In a large part of those cases, it would be possible to
identify the gene responsible for the QTL effect. The
candidate gene would be affected in cis by that locus,
whereas downstream genes would be influenced in trans
(Mackay, 2001; Quigley et al., 2009; Quigley and
Balmain, 2009). 
Finally, the next generation of sequencing
techniques, together with the culmination of the human
(Lander et al., 2001; Venter et al., 2001) and mouse
(Waterston et al., 2002) genome sequencing projects,
will be invaluable tools in the refinement of QTL.
Thanks to the conclusion of the human genome project it
is possible to spot most genes inside a specified location.
Additionally, thanks to next-generation sequencing, it
will be possible to explore candidate genes without the
presence of time-consuming genomic screening. The
refinement of QTL has improved since the whole
genome of more species has been sequenced
(Chimpanzee Sequencing and Analysis Consortium,
2005; Lindblad-Toh et al., 2005). This has allowed
recognition of evolutionary conserved sequence
domains, and the genetic differences among some of the
widely used inbred mouse strains (Frazer et al., 2007).
The sequence accessibility throughout species would
permit candidate gene recognition for all those traits
which have already been localized in several species
(Hunter and Crawford, 2008; DiPetrillo et al., 2005). In
the forthcoming years, as a consequence of these
technical innovations, we ought to refine several QTL
containing mouse cancer risk alleles and their
interactions, and analysed them in human populations
(Balmain, 2002). Moreover, it is possible that with the
advent of whole genome sequencing, positional cloning
may turn out to be unnecessary and fine mapping of
significant loci may result straight forward to their
isolation. The combination of mouse genetics studies
with new technologies provides a possibility to identify
the whole genetic arena that controls tumor
susceptibility, evolution and response to therapy. The
knowledge acquired by means of these genetic studies
will have a significant effect on medical sciences, and
should certainly lead to improved prognosis and therapy
of human cancer, leading to a more individualized
clinical management of the disease.
Pharmacogenomics
The variability of human responses to drug
treatments has prompted a range of studies that aim to
identify the genetic basis of this variation: a research
field that has been termed “pharmacogenetics” or
“pharmacogenomics” (Goldstein et al., 2003;
Weinshilboum, 2003). This field includes the study of
allelic variants that underlie individual differences in
clinical effectiveness, benign adverse drug reactions, and
severe, typically uncommon, adverse reactions.
It is now evident that differences in the DNA
sequence of genes involved with drug action can lead to
interindividual differences in effectiveness and adverse
reactions to therapeutic drugs. Pharmacogenomics raises
the possibility that drug discovery and patient
management could move from a “one drug fits all”
approach to one in which therapy is tailored to patients’
genomes. Genetically modified mice that mimic human
variation in drug response can provide one of the tools to
move the field towards these goals (Liggett, 2004).
Molecular image
Clearly, one crucial addition to the drug discovery
toolbox would be the development of novel and more
predictive models of drug effect and toxicity. In
particular, reporter animals could make a significant
contribution to drug discovery programs by facilitating
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target identification and improving the efficacy and
reliability of all phases of preclinical drug development.
In vivo reporter gene and imaging technologies have
the potential to contribute to the drug discovery pipeline
in several areas (Herranz and Sanchez-Garcia, 2007).
They provide systems that enable the study of the
biochemical activity of a target in disease, and in
response to a drug, to be monitored over periods of time,
and offer more accurate methods of measuring
pharmacodynamics and toxicity. Although reporter-gene
technology is in its infancy, with further refinement
reporter animals could become a valuable tool in the
early stages of target and lead identification and
preclinical drug development (Maggi and Ciana, 2005).
To help in testing these new drugs for safety and
efficacy, and to aid clinicians in selecting from the
various alternatives, diagnostic tools to detect the
molecular signature of cancer have become more
important (Sullivan and Kelloff, 2005). In this context,
molecular imaging is a valuable tool for basic
researchers and clinicians for several reasons. First,
molecular imaging is, in essence, an in vivo assay. The
greatest potential value of molecular imaging is its
ability to report on the molecular state of a tumour in its
normal milieu. Cancer cells do not behave in vitro the
same as they do in vivo-as soon as cells are removed
from the body, by biopsy for example, their pattern of
gene expression changes, reflecting the dependence of
the tumour cell on its microenvironment. This
information may be a better indicator of the effects of
targeted therapeutics than the molecular expression
observed in the same tumour cells when cultured.
Second, cancer-cell phenotypes change over time and if
such changes occur during the course of therapy, they
often result in resistance to the administered drug. Serial
information from molecular imaging can therefore assist
physicians in determining whether the current
therapeutic choices are still relevant in treating the
specific phenotype of the tumour. Third, cancer is often
distributed at various locations within an organ or
throughout the body. In vitro information from a single
biopsy may not reflect the full heterogeneity of
molecular changes that have taken place within the
tumour cells of a patient. Fourth, molecular imaging-
when used during therapeutic trials-can provide kinetic
and dynamic data on a drug that cannot be obtained from
a static biopsy (Green and Hudson, 2005).
Molecular imaging agents and methods have been
developed for a variety of systems using different forms
of energy. These include nuclear medicine methods-such
as positron emission tomography (PET) and single
photon emission computed tomography-magnetic
resonance imaging (MRI), ultrasound methods,
computed tomography (CT), and optical technologies.
Increasingly, methods with complementary strengths are
combined in clinical practice, such as the CT-PET
systems that are now commercially available (Sullivan
and Kelloff, 2005; Rudin and Weissleder, 2003).
In cancer therapy, in vivo imaging has become an
increasingly important tool in helping clinicians select
patients with the appropriate molecular phenotype for a
given therapeutic, provide quantitative information about
the optimum biological dose and timing of the therapy
(as opposed to the present paradigm of administering the
maximum tolerated dose) and assess appropriate
biological end points, which may not necessarily be the
reduction of tumour size.
We can use this new technology in our new mouse
models, so that while we are testing drugs in them, we
can study more aspects of the drugs than we are
currently doing in human clinical trial.
Molecular imaging assays in intact living animals
could be of further benefit in resolving biological
questions raised by pharmaceutical scientists. Transgenic
animals are useful in guiding early drug discovery by
"validating" the target protein, evaluating test
compounds, determining whether the target is involved
in any toxicological effects of test compounds, and
testing the efficacy of compounds to ensure that the
compounds will act as expected in man (Massoud and
Gambhir, 2003; Livingston, 1999).
Conclusions
There are many reasons why preclinical results do
not predict human clinical trials; one of them is the use
of inappropriate mouse models for preclinical assays.
Numerous agents have shown exciting activity in
preclinical models and yet have had minimal activity
clinically. Herein we have purposed some ways to solve
these obstacles.
The first thing to take into account is that the stem
cell is the cell in which the initiating mutation occurs in
human cancer. Mouse models in which technology is
based on specifically expressing human genetic
alterations in somatic stem cell will accurately reproduce
the human disease. The generation of mouse models
reproducing human cancer pathology will be a
prerequisite not only for understanding the genesis and
maintenance of human cancer, but also for the
development of molecular and pharmacological
therapeutics to treat and prevent human cancer. New
drugs must be designed against the mechanisms that are
responsible for the maintenance of the CSC, not for the
initial event that transformed normal stem cells to CSC,
because it is possible that the first alteration of the CSC
will retain no function in the subsequent steps of cancer
development. Targets selected in this context should be
validated in a disease state by comparative genomics and
pathology. Live animal imaging enables us to estimate
functional genomics and target validation. Once the
target has been validated, we must select those animals
that are sensitive to the agents from those that do not
respond. These results should guide us on whether or not
to use that agent in human clinical trials so we can be
selective and effective, rather than with the current
preclinical trials. The last thing to do is to design human
clinical trials by taking into account the results of the
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preclinical assays. The clinical setting proposed herein
will reduce the number of agents that goes into a clinical
trial, being able to expend more effort on ones with a
potential benefit. 
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